Cellmid Ltd
ASX:CDY
Intrinsic Value
Cellmid Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CDY.
Fundamental Analysis
Balance Sheet Decomposition
Cellmid Ltd
Current Assets | 11.3m |
Cash & Short-Term Investments | 6.7m |
Receivables | 1.8m |
Other Current Assets | 2.8m |
Non-Current Assets | 2m |
PP&E | 579.9k |
Intangibles | 1.4m |
Current Liabilities | 1.9m |
Accounts Payable | 682.2k |
Accrued Liabilities | 261.7k |
Other Current Liabilities | 971.3k |
Non-Current Liabilities | 943.5k |
Long-Term Debt | 844k |
Other Non-Current Liabilities | 99.5k |
Earnings Waterfall
Cellmid Ltd
Revenue
|
5.8m
AUD
|
Cost of Revenue
|
-2.1m
AUD
|
Gross Profit
|
3.7m
AUD
|
Operating Expenses
|
-7.7m
AUD
|
Operating Income
|
-4m
AUD
|
Other Expenses
|
620.2k
AUD
|
Net Income
|
-3.4m
AUD
|
Free Cash Flow Analysis
Cellmid Ltd
CDY Profitability Score
Profitability Due Diligence
Cellmid Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Cellmid Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
CDY Solvency Score
Solvency Due Diligence
Cellmid Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Cellmid Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDY Price Targets Summary
Cellmid Ltd
Shareholder Return
CDY Price
Cellmid Ltd
Average Annual Return | -22.7% |
Standard Deviation of Annual Returns | 35.4% |
Max Drawdown | -86% |
Market Capitalization | 10.9m AUD |
Shares Outstanding | 220 216 992 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cellmid Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-12-09. The firm is specialized in developing anti-aging solutions. The firm operates through two segments: Diagnostics and Consumer Health. The firm is engaged in the research and development of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine. The company is also engaged in the development and sale of over the counter (OTC) and cosmetic products for hair loss and anti-aging hair care through its FGF5 inhibitor technology. The company has developed a range of products under the evolis, evolis Professional, Lexilis Hybrid, Jo-JuRED and Lexilis BLACK brands.